EBR Systems, Inc.

EBR Systems, Inc. is a medical device company based in Silicon Valley, founded in 2003. The company specializes in leadless therapies for cardiac rhythm management, particularly focusing on cardiac resynchronization therapy (CRT) to address heart rhythm diseases and heart failure. EBR is headquartered in Sunnyvale, California, and employs 86 people. The company has raised $200.9 million in funding and generates approximately $21.6 million in revenue. The flagship product, the WiSE Cardiac Resynchronization Therapy (CRT) system, features leadless endocardial pacing technology. This innovative system provides a more physiologic approach to heart pacing and has achieved significant milestones, including the world's first totally leadless CRT implant in 2018 and FDA Breakthrough Device Designation in 2019. EBR is committed to advancing cardiac rhythm management by combining clinical insights with technology, supporting healthcare professionals and institutions in delivering effective treatments. The company fosters a team-oriented culture, emphasizing values such as patient care and collaboration.